EQL Pharma AB

As of June 30, 2026, EQL Pharma AB carries a market capitalization of 699.85M, placing it among publicly traded companies globally. Its enterprise value stands at 1.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

EQL Pharma AB's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, EQL Pharma AB has 29.53M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.54, and the price-to-book ratio stands at 2.80.

As of June 30, 2026, EQL Pharma AB trades at an EV/EBITDA multiple of 35.67 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 35.67 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.12B versus a market cap of 699.85M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, EQL Pharma AB maintains a current ratio of 1.83, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 193.51, indicating elevated leverage, while an interest coverage ratio of 1.04 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, EQL Pharma AB posted a negative return on equity (ROE) of -0.36, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) is negative at -2.81, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) is negative at -0.10, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -2.83, pointing to unprofitable operations over the period. The company generates approximately 20.60M in revenue per employee across its workforce of 22.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.61 indicates how many times EQL Pharma AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, EQL Pharma AB recorded 2.19M in income tax expense. That works out to an effective tax rate of 163.34, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.34M, leaving -851,000.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, EQL Pharma AB's stock has declined approximately 65.24% over the past 52 weeks. The 50-day moving average sits at 24.43, while the 200-day moving average is 37.08.

Over the twelve months ended June 30, 2026, EQL Pharma AB generated 453.19M in revenue and converted that into -851,000.00 in net income, yielding earnings per share of -0.03. EBITDA reached 31.48M, while operating income came in at 31.48M.

As of June 30, 2026, EQL Pharma AB holds 61.10M in cash and equivalents against 484.37M in total debt, resulting in a net debt position of -36.42M. Total book value stands at 250.31M, with working capital of 164.74M providing operational flexibility.

EQL Pharma AB produced 16.73M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -74.29M in capital expenditures, free cash flow totaled -57.55M - equivalent to -1.96 per share.

Over the twelve months ended June 30, 2026, EQL Pharma AB posted a gross margin of 32.72, reflecting its pricing power and cost economics. The operating margin of 6.95 and net profit margin of -0.19 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -8.08: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.91, meaning EQL Pharma AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

EQL Pharma AB's most recent stock split took place on October 23, 2018.